Heartbeats, Burdens, and Biofixtures

2021 ◽  
Vol 30 (2) ◽  
pp. 285-296
Author(s):  
KELSEY GIPE

AbstractThis paper addresses a dichotomy in the attitudes of some clinicians and bioethicists regarding whether there is a moral difference between deactivating a cardiac pacemaker in a highly dependent patient at the end of life, as opposed to standard cases of withdrawal of treatment. Although many clinicians hold that there is a difference, some bioethicists maintain that the two sorts of cases are morally equivalent. The author explores one potential morally significant point of difference between pacemakers and certain other life-sustaining treatments: specifically, that the former are biofixtures, which become part of the patient in a way that the latter do not. The concept of the pacemaker as biofixture grants pacemakers a unique moral status that gives reason to treat a pacemaker the same as other parts of the patient that are necessary to sustain life. The author employs this biofixture analysis to affirm the intuition that deactivating a pacemaker in a highly dependent patient at the end of life is, in moral terms, more analogous to active euthanasia than it is to standard cases of withdrawal of treatment. The paper concludes with consideration of potential implications for further implantable medical technologies, such as ventricular assist devices and total artificial hearts.

Author(s):  
Gaurav Girdhar ◽  
Yared Alemu ◽  
Michalis Xenos ◽  
Jawaad Sheriff ◽  
Jolyon Jesty ◽  
...  

Flow past mechanical heart valves (MHV) in mechanical circulatory support devices including total artificial hearts and ventricular assist devices, is primarily implicated in thromboembolism due to non-physiological flow conditions where the elevated stresses and exposure times are sufficiently high to cause platelet activation and thrombus formation. Mitigation of this risk requires lifelong anticoagulation therapy and less thrombogenic MHV designs should therefore be developed by device manufacturers [1].


2010 ◽  
Vol 34 (9) ◽  
pp. 699-702 ◽  
Author(s):  
Takashi Yamane ◽  
Shunei Kyo ◽  
Hikaru Matsuda ◽  
Yusuke Abe ◽  
Kou Imachi ◽  
...  

ICU Director ◽  
2012 ◽  
Vol 4 (1) ◽  
pp. 15-21
Author(s):  
Ravi V. Joshi

Since 2001, ventricular assist devices (VADs), total artificial hearts, and a growing number of devices have become increasingly more commonplace options to heart failure management and viable alternatives to heart transplantation. Cardiothoracic step-down and intensive care units will likely be managing more and more patients on mechanical circulation in the future. This review will briefly give an introduction to VAD function, types of VADs, the characteristics of VAD patients, and management issues in the ICU that may arise with these patients.


Perfusion ◽  
2003 ◽  
Vol 18 (4) ◽  
pp. 245-251 ◽  
Author(s):  
Georg Matheis

‘The artificial lung especially has lingered behind progress with artificial hearts and ventricular assist devices, not because the need for lungs has not been recognized, but because we have not had a full understanding of the engineering problems and the unique material requirements until recent years.’1 Brack Hattler, MD PhD The development from the first clinical use of haemo-dialysis over five decades ago to widespread chronic treatment took more than two decades. The histories of other artificial organ technologies, such as artificial hearts, follow similar long development paths. For five decades, due to a lack of technology, artificial lungs have been limited to use with a heart-lung machine for cardiopulmonary bypass (CPB) or extracorporeal membrane oxygenation (ECMO). The advent of pumpless biocompatible artificial lungs will open new treatment options for patients with acute or chronic lung failure.


Sign in / Sign up

Export Citation Format

Share Document